These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38915622)

  • 1. Chromogranin A (CgA) Deficiency Attenuates Tauopathy by Altering Epinephrine-Alpha-Adrenergic Receptor Signaling.
    Jati S; Munoz-Mayorga D; Shahabi S; Tang K; Tao Y; Dickson DW; Litvan I; Ghosh G; Mahata SK; Chen X
    bioRxiv; 2024 Jun; ():. PubMed ID: 38915622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A Deficiency Attenuates Tauopathy by Altering Epinephrine-Alpha-Adrenergic Receptor Signaling.
    Mahata S; Jati S; Munoz-Mayorga D; Shahabi S; Tang K; Tao Y; Dickson D; Litvan I; Ghosh G; Chen X
    Res Sq; 2024 Aug; ():. PubMed ID: 39149499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation.
    Barron MR; Gartlon J; Dawson LA; Atkinson PJ; Pardon MC
    Front Immunol; 2020; 11():293. PubMed ID: 32194553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nogo-A Drives Alzheimer's Disease Progression by Inducing Tauopathy Vulnerability.
    Wang Z; Pan JP; Geng J; Lv S; Chen G; Fang N; Zhang Z; Li J; Xu X; Wang R; Zheng Q; Yan L; Chen G; Xiao F
    Aging Dis; 2024 May; ():. PubMed ID: 38916730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common and Specific Marks of Different Tau Strains Following Intra-Hippocampal Injection of AD, PiD, and GGT Inoculum in hTau Transgenic Mice.
    Ferrer I; Andrés-Benito P; Carmona M; Del Rio JA
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole Genome Expression Analysis in a Mouse Model of Tauopathy Identifies MECP2 as a Possible Regulator of Tau Pathology.
    Maphis NM; Jiang S; Binder J; Wright C; Gopalan B; Lamb BT; Bhaskar K
    Front Mol Neurosci; 2017; 10():69. PubMed ID: 28367114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal loss and inflammation preceding fibrillary tau pathology in a rat model with early human-like tauopathy.
    Emmerson JT; Malcolm JC; Do Carmo S; Nguyen P; Breuillaud L; Martinez-Trujillo JC; Cuello AC
    Neurobiol Dis; 2023 Oct; 187():106317. PubMed ID: 37802153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
    Maphis N; Jiang S; Xu G; Kokiko-Cochran ON; Roy SM; Van Eldik LJ; Watterson DM; Lamb BT; Bhaskar K
    Alzheimers Res Ther; 2016 Dec; 8(1):54. PubMed ID: 27974048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of CSF chromogranin A to discriminate between Alzheimer's disease and dementia with Lewy bodies.
    Bousiges O; Lavaux T; Demuynck C; Schaeffer-Agalède C; Philippi N; Muller C; Cretin B; Blanc F
    Neuropathol Appl Neurobiol; 2024 Feb; 50(1):e12961. PubMed ID: 38363175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L; Egebjerg J; Barkholt P; Volbracht C
    Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy.
    Rossi F; Geiszler PC; Meng W; Barron MR; Prior M; Herd-Smith A; Loreto A; Lopez MY; Faas H; Pardon MC; Conforti L
    Behav Brain Res; 2018 Feb; 339():140-152. PubMed ID: 29175372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice.
    Chalermpalanupap T; Schroeder JP; Rorabaugh JM; Liles LC; Lah JJ; Levey AI; Weinshenker D
    J Neurosci; 2018 Jan; 38(1):74-92. PubMed ID: 29133432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement C3a receptor antagonist alleviates tau pathology and ameliorates cognitive deficits in P301S mice.
    Yao Y; Chang Y; Li S; Zhu J; Wu Y; Jiang X; Li L; Liu R; Ma R; Li G
    Brain Res Bull; 2023 Aug; 200():110685. PubMed ID: 37330021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Chromogranin A deficiency on catecholamine storage, catecholamine granule morphology and chromaffin cell energy metabolism in vivo.
    Pasqua T; Mahata S; Bandyopadhyay GK; Biswas A; Perkins GA; Sinha-Hikim AP; Goldstein DS; Eiden LE; Mahata SK
    Cell Tissue Res; 2016 Mar; 363(3):693-712. PubMed ID: 26572539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant Neuronal Tau Deposition and FKBP52 Decrease Is an Early Feature of Different Human and Experimental Tauopathies.
    Meduri G; Guillemeau K; Daguinot C; Dounane O; Genet M; Ferrara L; Chambraud B; Baulieu EE; Giustiniani J
    J Alzheimers Dis; 2023; 94(1):313-331. PubMed ID: 37248902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human tau expression reduces adult neurogenesis in a mouse model of tauopathy.
    Komuro Y; Xu G; Bhaskar K; Lamb BT
    Neurobiol Aging; 2015 Jun; 36(6):2034-42. PubMed ID: 25863528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
    Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of a Tauopathy Model of Alzheimer's Disease.
    Dengler-Crish CM; Smith MA; Wilson GN
    J Alzheimers Dis; 2017; 55(4):1605-1619. PubMed ID: 27814296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy.
    Chang JK; Leso A; Subaiea GM; Lahouel A; Masoud A; Mushtaq F; Deeb R; Eid A; Dash M; Bihaqi SW; Zawia NH
    Curr Alzheimer Res; 2018; 15(7):655-663. PubMed ID: 29357795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.